Phase 2 study of NS-17 (azacitidine) in acute myeloid leukemia
First written in FY2018-Q3. 8 of 11 entries say "Restated". Latest entry: FY2021.
No other company in this theme has enough history to compare yet.
- FY2021AchievedAnnual report
「For NS-17 (generic name: azacitidine), we obtained approval in March 2021 for an additional indication of acute myeloid leukemia.」
NS-17 progressed from the approval application submitted in September 2020 and obtained approval for the additional indication of acute myeloid leukemia in March 2021. - FY2021-Q3RestatedAnnual report
「• For NS-17 (generic name: azacitidine), we submitted an application for approval in September 2020 for acute myeloid leukemia as an indicated disease.」
The status of NS-17 at the approval application stage in September 2020 is restated. - FY2021-Q2AdvancedAnnual report
「• For NS-17 (generic name: azacitidine), we submitted an application for approval in September 2020 for acute myeloid leukemia as an indicated disease.」
NS-17 progressed from the Phase 2 study stage in acute myeloid leukemia to the approval application stage in September 2020. - FY2021-Q1RestatedAnnual report
「• A Phase 2 study of NS-17 (generic name: azacitidine) in acute myeloid leukemia is ongoing.」
The Phase 2 study of NS-17 in acute myeloid leukemia is ongoing. - FY2020-Q3RestatedAnnual report
「For NS-17 (generic name: azacitidine), a Phase 2 study in acute myeloid leukemia has been ongoing since January 2018.」
The Phase 2 study of NS-17 in acute myeloid leukemia is ongoing. - FY2020-Q2RestatedAnnual report
「• For NS-17 (generic name: azacitidine), a Phase 2 study in acute myeloid leukemia has been ongoing since January last year.」
The Phase 2 study of NS-17 in acute myeloid leukemia is ongoing. - FY2020-Q1RestatedAnnual report
「• For NS-17 (generic name: azacitidine), a Phase 2 study in acute myeloid leukemia has been ongoing since January last year.」
The Phase 2 study of NS-17 in acute myeloid leukemia is ongoing. - FY2019-Q3RestatedAnnual report
「• For NS-17 (generic name: azacitidine), we began a Phase 2 study in acute myeloid leukemia in January last year.」
The status of the Phase 2 study of NS-17 in acute myeloid leukemia is restated. - FY2019-Q2RestatedAnnual report
「• For NS-17 (generic name: azacitidine), we began a Phase 2 study in acute myeloid leukemia in January this year.」
The status of the Phase 2 study of NS-17 in acute myeloid leukemia, which began in January this year, is restated. - FY2019-Q1RestatedAnnual report
「• For NS-17 (generic name: azacitidine), we began a Phase 2 study in acute myeloid leukemia in January this year.」
The status of the Phase 2 study of NS-17 in acute myeloid leukemia, which began in January this year, is restated. - FY2018-Q3First statedAnnual report
「• For NS-17 (generic name: azacitidine), we began a Phase 2 study in acute myeloid leukemia in January this year.」
The first mention was made that a Phase 2 study of NS-17 in acute myeloid leukemia began in January 2018.